REYOBIQ™ (rhenium re186 obisbemeda) is an investigational radiotherapeutic agent that is currently under clinical investigation by Plus Therapeutics, Inc. It has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for commercial use. The safety and efficacy of REYOBIQ™ have not been established and are being evaluated in ongoing clinical trials.

Information provided about REYOBIQ™ is for educational and informational purposes only and should not be considered medical advice. Patients should consult with their healthcare providers regarding treatment decisions. Participation in clinical trials is subject to eligibility criteria and regulatory approval.

For more information, please visit Plus Therapeutics or refer to clinical trial listings at ClinicalTrials.gov.